4th May 2026
28th April 2026
US FDA Accepts New Drug Application for Cullinan Therapeutics’ Zipalertinib for Treatment of Non-Small Cell Lung Cancer
30th March 2026
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519
18th March 2026
Crossbow Therapeutics Raises $77 Million in Series B Financing to Advance Development of TCR-mimetic Antibody Therapies to Treat Cancer
24th February 2026
Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate
23rd February 2026
FDA Grants Reunion’s RE104 Breakthrough Therapy Designation in Postpartum Depression
9th February 2026
Lilly to acquire Orna Therapeutics to advance cell therapies
9th January 2026
Aktis Oncology Announces Pricing of its Upsized Initial Public Offering
22nd September 2025
The Endpoints 11: Umoja Biopharma looks to finally break through the barriers that restrict CAR-T
16th September 2025